Compare AbbVie Inc (ABBV) vs Plug Power Inc (PLUG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbbVie Inc vs Plug Power Inc — how do they compare? AbbVie Inc trades at $248 (market cap $438.19B), while Plug Power Inc trades at $2.22 (market cap $2.94B). The key difference: AbbVie Inc is far larger — about 149× Plug Power Inc's market cap, and AbbVie Inc pays a 2.79% dividend while Plug Power Inc pays none. Which is the better fit depends on your goals.
| ABBV | PLUG | |
|---|---|---|
Market Cap | $438.19B | $2.94B |
Sector | Health | Industrials |
52-Week High | $263.58 | $4.14 |
52-Week Low | $197.38 | $1.41 |
Enterprise Value | $502.45B | $3.73B |
Dividend Yield | 2.79% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $248.47, up 0.99% with a bullish technical signal supported by moving averages and oversold RSI levels. The company demonstrates strong revenue growth with 2025 revenue reaching $61.16B and consistent earnings beats in recent quarters. Recent positive clinical trial results for ovarian cancer treatment and institutional accumulation signal confidence in the company's pipeline and growth trajectory.
AbbVie presents a compelling investment case with 71% analyst buy ratings and a $281.33 consensus price target offering 13% upside. Key risks include patent cliffs in the 2030s and high debt levels, but robust immunology portfolio growth and dividend aristocrat status provide stability. The stock's current valuation metrics suggest premium pricing relative to historical levels.
Plug Power (PLUG) trades at $2.18, up 5.31% with a bearish technical signal despite recent earnings beat. The company shows improving operational metrics with reduced cash usage and margin improvements, though it remains unprofitable with negative gross margins of -25.66%. Management targets positive EBITDA by Q4 2026 while navigating significant liquidity challenges through asset sales and financing activities.
While analyst consensus leans bullish with a $2.22 price target, PLUG faces substantial execution risks amid persistent losses and cash burn. The stock offers speculative upside if management delivers on profitability targets, but investors face elevated risk from the company's negative cash flow and competitive hydrogen market pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Plug Power Inc
Plug Power is building an end-to-end green hydrogen ecosystem—from production, storage and delivery to energy generation. The company plans to build and operate green hydrogen highways across North America and Europe. Plug will deliver its green hydrogen solutions directly to its customers and through joint venture partners into multiple end markets—including material handling, e-mobility, power generation, and industrial applications.
Read more on PLUG →
